Minerva Neurosciences (NERV) Price & Analysis

Compare

608 Followers

NERV Stock Chart & Stats

$3.25

-$0.09(-3.83%)

At close: Jan 08 4:00 PM EST

$3.25

-$0.09(-3.83%)

Day’s Range― - ―

52-Week Range$1.15 - $12.46

Previous CloseN/A

Volume1.19K

Average Volume (3M)465.60K

Market Cap

$25.67M

Enterprise Value$57.67M

Total Cash (Recent Filing)$12.29M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)2.5

Beta1.60

Next Earnings

Mar 10, 2026

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.36

Shares Outstanding6,993,406

10 Day Avg. Volume1,362,901

30 Day Avg. Volume465,600

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)>-0.01

Price to Sales (P/S)0.00

P/FCF Ratio-0.86

Enterprise Value/Market Cap2.25

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-42.37K

Enterprise Value/Ebitda-5.62

Forecast

1Y Price Target

$4.50

Price Target Upside38.46% Upside

Rating ConsensusHold

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPhase IIb and Phase III efficacy data suggest roluperidone is active, showing benefits for negative symptoms of schizophrenia.

Regulatory ApprovalFDA recognized negative symptoms of schizophrenia as a high unmet need, which supports the potential for roluperidone to fill this gap.

Stock Price PotentialThe potential stock upside is significant, with estimates of 100-300% increase upon positive Phase III data.

Bears Say

Execution RiskExecution remains a risk due to the need for clarity on precise timelines for the Phase III trial.

Study DelaysFrustration exists that the company did not embark on the new study immediately after the previous trial narrowly missed its primary endpoint.

Minerva Neurosciences News

Minerva price target raised to $5 from $3 at Jefferies

Jefferies raised the firm’s price target on Minerva (NERV) to $5 from $3 and keeps a Hold rating...

3d ago

NERV

Minerva appoints Kaul to board of directors

Minerva (NERV) Neurosciences, announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the...

15d ago

NERV

Minerva price target lowered to $4 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Minerva (NERV) to $4 from $5 and keeps a Neutral...

28d ago

NERV

Minerva reports Q3 EPS (36c) vs $2.97 last year

“Strengthened by the recent financing and our alignment with FDA on a confirmatory Phase 3 clinical trial, we...

29d ago

NERV

Minerva Neurosciences Expands Board Amid Fundraising Effort

Minerva Neurosciences ( ($NERV) ) has shared an update. On November 14, 2025, Minerva Neurosciences appointed Dr. Inderjit...

15d ago

NERV

Minerva Neurosciences Reports Q3 2025 Financial Results

Minerva Neurosciences ( ($NERV) ) has released its Q3 earnings. Here is a breakdown of the information Minerva...

23d ago

NERV

Minerva Neurosciences Secures $200M for Drug Trials

The latest update is out from Minerva Neurosciences ( ($NERV) ). On October 21, 2025, Minerva Neurosciences announced...

1M ago

NERV

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

TipRanks offers insight into the biggest stock market stories worth reading on Tuesday. ...

1M ago

Why Is Minerva Neurosciences Stock (NERV) Up 165% Today?

Minerva Neurosciences stock soared on Tuesday after the company announced a securities purchase agreement. ...

1M ago

NERV

Minerva announces financing of up to $200M to advance roluperidone

Minerva (NERV) Neurosciences entered into a securities purchase agreement with certain institutional investors that will provide up to...

1M ago

NERV

Minerva Neurosciences Reports Q2 2025 Financial Results

Minerva Neurosciences ( ($NERV) ) has released its Q2 earnings. Here is a breakdown of the information Minerva...

4M ago

NERV

NERV Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Minerva Neurosciences (NERV) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street analysts...

4M ago

NERV

Minerva Neurosciences Reports Q1 2025 Earnings and Regulatory Challenges

Minerva Neurosciences ( ($NERV) ) has released its Q1 earnings. Here is a breakdown of the information Minerva...

6M ago

NERV

Minerva reports Q1 EPS (50c) vs ($1.13) last year

Cash, cash equivalents and restricted cash at March 31, 2025 were approximately $17.4 million, as compared to $21.5...

7M ago

NERV

NERV FAQ

What was Minerva Neurosciences’s price range in the past 12 months?

Minerva Neurosciences lowest stock price was $1.15 and its highest was $12.46 in the past 12 months.

What is Minerva Neurosciences’s market cap?

Minerva Neurosciences’s market cap is $25.67M.

When is Minerva Neurosciences’s upcoming earnings report date?

Minerva Neurosciences’s upcoming earnings report date is Mar 10, 2026 which is in 96 days.

How were Minerva Neurosciences’s earnings last quarter?

Minerva Neurosciences released its earnings results on Nov 05, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.36.

Is Minerva Neurosciences overvalued?

According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Minerva Neurosciences pay dividends?

Minerva Neurosciences does not currently pay dividends.

What is Minerva Neurosciences’s EPS estimate?

Minerva Neurosciences’s EPS estimate is -0.3.

How many shares outstanding does Minerva Neurosciences have?

Minerva Neurosciences has 6,993,406 shares outstanding.

What happened to Minerva Neurosciences’s price movement after its last earnings report?

Minerva Neurosciences reported an EPS of -$0.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.087%.

Which hedge fund is a major shareholder of Minerva Neurosciences?

Currently, no hedge funds are holding shares in NERV

Company Description

Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is engaged in creating innovative therapies for patients suffering from neuropsychiatric disorders, including schizophrenia, depression, and Parkinson's disease, with its core product candidates being roluperidone and MIN-301.

Minerva Neurosciences (NERV) Earnings & Revenues

Historic Earnings Reports

NERV Stock 12 Month Forecast

Average Price Target

$4.50

▲(38.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Aug<br/>2024","9":"Feb<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.8,3.8923076923076922,3.9846153846153847,4.076923076923077,4.1692307692307695,4.2615384615384615,4.3538461538461535,4.446153846153846,4.538461538461538,4.63076923076923,4.723076923076923,4.815384615384615,4.907692307692308,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.8,3.8538461538461535,3.9076923076923076,3.9615384615384612,4.015384615384615,4.069230769230769,4.123076923076923,4.176923076923077,4.230769230769231,4.2846153846153845,4.338461538461538,4.392307692307693,4.446153846153846,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.8,3.815384615384615,3.8307692307692305,3.846153846153846,3.8615384615384616,3.876923076923077,3.8923076923076922,3.9076923076923076,3.923076923076923,3.9384615384615382,3.953846153846154,3.9692307692307693,3.9846153846153847,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.6,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1690848000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.96,"date":1698796800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.65,"date":1706745600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >